Brief: China Medical System Gains Exclusive License For Oral Small-Molecule Jak1 Inhibitor Povorcitinib
April 1 (Reuters) - China Medical System Holdings Ltd
0867.HK :
* GAINING EXCLUSIVE LICENSE FOR ORAL SMALL-MOLECULE JAK1
INHIBITOR
POVORCITINIB
* GROUP, VIA UNIT, ENTERED A COLLABORATION AND LICENSE
AGREEMENT
WITH INCYTE CORP
* COLLABORATION AND LICENSE AGREEMENT FOR SELECTIVE ORAL
SMALLMOLECULE JAK1 INHIBITOR POVORCITINIB
Further company coverage: 0867.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Medical System Holdings
See all newsBrief: China Medical System Says CMS-D001 Granted Drug Clinical Trial Approval Notice By NMPA
Brief: China Medical System Holdings Says Dermavon Receives NMPA Approval For Lumirix NDA For Atopic Dermatitis
China Medical System climbs most in six weeks on higher profit, dividend
China Medical System H1 revenue rises on jump in sales of innovative and exclusive products
AI shortens drug discovery to around 1 year in China, Insilico CEO says